The optimal duration of treatment for skin and soft tissue infections and acute bacterial skin and skin structure infections

Corcione, Silvia; Rosa, Francesco Giuseppe De

doi:10.1097/qco.0000000000000440

Cited by 12 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In real-life clinical practice, a change in antibiotic treatment is recommended if signs and symptoms of skin infections do not improve or if the patient deteriorates at an early stage of management and/or when microbiological information becomes available and escalation or deescalation of antibiotic treatment is required (31). In the current study, the blinded investigators continued the study drug therapy based on the overall assessment of clinical status in approximately 90% of patients in both treatment arms at 48 to 72 h and at day 7.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection

Alder

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infection (ABSSSI) caused by Gram-positive bacteria in the United States, Europe, and other countries. In this multicenter, double-blind, phase 3 study, 598 adult ABSSSI patients in China, Taiwan, the Philippines, and the United States were randomized to receive 200 mg of tedizolid, intravenously (i.v.)/orally (p.o.), once daily for 6 days or 600 mg of linezolid, i.v./p.o. twice daily for 10 days. The primary endpoint was early clinical response rate at 48 to 72 h. Secondary endpoints included programmatic and investigator-assessed outcomes at end-of-therapy (EOT) and posttherapy evaluation (PTE) visits. Safety was also evaluated. In the intent-to-treat (ITT) population, 75.3% of tedizolid-treated patients and 79.9% of linezolid-treated patients were early responders (treatment difference, –4.6%; 95% confidence interval [CI], –11.2, 2.2). After exclusion of patients who never received the study drug (tedizolid, n = 8; linezolid, n = 1; modified ITT), comparable early response rates were observed (tedizolid, 77.4%; linezolid, 80.1%; treatment difference, –2.7%; 95% CI, –9.4, 3.9). Secondary endpoints showed high and similar clinical success rates in the ITT and clinically evaluable (CE) populations at EOT and PTE visits (e.g., CE-PTE for tedizolid, 90.4%; for linezolid, 93.5%). Both drugs were well tolerated, and no death occurred. Eight patients experienced phlebitis with tedizolid while none did with linezolid; hence, drug-related treatment-emergent adverse events were reported in a slightly higher proportion in the tedizolid (20.9%) arm than in the linezolid arm (15.8%). The study demonstrated that tedizolid in a primarily Asian population was an efficacious and well-tolerated treatment option for ABSSSI patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT02066402.)

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection

Alder

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Evidence for antibiotic treatment is also provided in several reports: 8-13 days for erysipelas, 10-14 days for cellulitis, 4-28 days for SSTI, and from one dose of antibiotic to 14 days for ABSSSI and cSSTI [10,60,89]. In addition, adherence to antibiotic guidelines leads to favourable outcomes in patients with SSTI [95,96].…”

Section: Current Recommendations For Antibiotic Treatment Durationmentioning

confidence: 99%

“…In addition, adherence to antibiotic guidelines leads to favourable outcomes in patients with SSTI [95,96]. Over 7 days are needed for necrotizing infection, patients with diabetes or elderly patients [89]. However, if a patient requires in-hospital intravenous treatment, this does not mean that treatment should be extended beyond what is necessary [97].…”

Section: Current Recommendations For Antibiotic Treatment Durationmentioning

confidence: 99%

See 1 more Smart Citation

Current international and national guidelines for managing skin and soft tissue infections

Bouza

Burillo

2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewSkin and soft tissue infections account for a significant percentage of both community and nosocomial infections. Several nosological entities are included in this concept. However, there is a very scarce body of doctrine for their treatment based on randomised trials. Therefore, we considered it necessary to review current treatment guidelines to bring new recommendations and improvements to our colleagues. In this review of recent literature, we identified updated guidelines in this area by searching the databases PubMed, evidence-based medicine online, York University reviewers group, Cochrane, MBE-Trip and Sumsearch using the terms: soft tissue infection, therapy, guideline. Recent findingsDevelopments focus on using new antimicrobials and on the prescription of shorter antibiotic treatment courses.

show abstract

“…SSTIs constitute the most common infectious disease in all age groups, and their incidence is increasing every year with the increase in surgical procedures, the use of immunosuppressive drugs, and cancer (7). SSTIs often require inpatient treatment and place a great burden on the health care system (8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

The causal relationship between obesity and skin and soft tissue infections: A two-sample Mendelian randomization study

Mei

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveMany observational studies have shown that obesity strongly affects skin and soft tissue infections (SSTIs). However, whether a causal genetic relationship exists between obesity and SSTIs is unclear.MethodsA two-sample Mendelian randomization (MR) study was used to explore whether obesity is causally associated with SSTIs using a publicly released genome-wide association study (GWAS). An inverse-variance weighted (IVW) analysis was used as the primary analysis, and the results are reported as the odds ratios (ORs). Heterogeneity was tested using Cochran’s Q test and the I2 statistic, and horizontal pleiotropy was tested using the MR−Egger intercept and MR pleiotropy residual sum and outlier (MR-PRESSO).ResultsThe results of the MR analysis showed a positive effect of BMI on SSTIs (OR 1.544, 95% CI 1.399-1.704, P= 5.86 × 10-18). After adjusting for the effect of type 2 diabetes (T2D) and peripheral vascular disease (PVD), the positive effect still existed. Then, we further assessed the effect of BMI on different types of SSTIs. The results showed that BMI caused an increased risk of impetigo, cutaneous abscess, furuncle and carbuncle, cellulitis, pilonidal cyst, and other local infections of skin and subcutaneous tissues, except for acute lymphadenitis. However, the associations disappeared after adjusting for the effect of T2D and PVD, and the associations between BMI and impetigo or cellulitis disappeared. Finally, we assessed the effects of several obesity-related characteristics on SSTIs. Waist circumference, hip circumference, body fat percentage, and whole-body fat mass, excluding waist-to-hip ratio, had a causal effect on an increased risk of SSTIs. However, the associations disappeared after adjusting for the effect of BMI.ConclusionThis study found that obesity had a positive causal effect on SSTIs. Reasonable weight control is a possible way to reduce the occurrence of SSTIs, especially in patients undergoing surgery.

show abstract

The optimal duration of treatment for skin and soft tissue infections and acute bacterial skin and skin structure infections

Cited by 12 publications

References 47 publications

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection

Current international and national guidelines for managing skin and soft tissue infections

The causal relationship between obesity and skin and soft tissue infections: A two-sample Mendelian randomization study

Contact Info

Product

Resources

About